Nasdaq

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- The business combination of two AI-powered drug discovery and development companies, Recursion (Nasdaq: RXRX) and Exscientia has been completed, with ...
CNBC

Recursion gets FDA approval to begin phase 1 trials of AI-discovered cancer treatment

AI drug pioneer Recursion Pharmaceuticals said Wednesday that one of its experimental treatments hit a key milestone. Recursion was able to use its artificial intelligence-enabled drug discovery ...
Nasdaq

Recursion, Exscientia shareholders approve proposed combination

Recursion (RXRX) and Exscientia plc (EXAI) have each received overwhelming approval from their shareholders for the proposed combination between Recursion and Exscientia. The transaction is expected ...